Executive Vice President Andrea Wainer Sells 42,500 Shares of Abbott Laboratories
On January 29, 2024, Executive Vice President Andrea Wainer executed a sale of 42,500 shares of Abbott Laboratories (NYSE:ABT), as reported in a recent SEC Filing. Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Over the past year, the insider has sold a total of 76,805 shares and has not made any purchases of the company's stock. The latest transaction is part of a trend observed over the past year, where there have been no insider buys and 22 insider sells for Abbott Laboratories.
On the date of the insider's recent transaction, shares of Abbott Laboratories were trading at $112.5, resulting in a market capitalization of $198.17 billion. The stock's price-earnings ratio stands at 35.02, which is above both the industry median of 27.07 and the company's historical median price-earnings ratio.
According to the GuruFocus Value chart, with a share price of $112.5 and a GF Value of $108.52, Abbott Laboratories has a price-to-GF-Value ratio of 1.04, indicating that the stock is Fairly Valued.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at Abbott Laboratories.
The GF Value image provides a visual representation of the stock's current valuation in relation to its intrinsic value as estimated by GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
